title: Treatment of hand and foot psoriasis with emphasis on efalizumab.
abstract: Hand and foot psoriasis is a chronic and debilitating disease that manifests as plaque-type or pustular-type lesions. Although the palms and soles represent only 2% of the total body surface area, psoriasis of these regions may lead to physical dysfunctions that can greatly impair dexterity, mobility, and the quality of life of affected individuals. Deregulation of T-lymphocyte-mediated immune response is important in the pathophysiology of psoriasis. Efalizumab (Raptiva, Genentech) is an anti-CD11a monoclonal antibody that disrupts the interaction between T cells and antigen-presenting cells, thereby inhibiting various T-cell-mediated immune processes that include activation and trafficking. Recent evidence indicates that efalizumab may be beneficial for patients with hand and foot psoriasis.
authors: Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors: L
authors: L
authors: Kircik
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen / Q000187:drug effects; D005534:Foot Diseases / Q000188:drug therapy* / Q000503:physiopathology; D006225:Hand; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen; C472181:efalizumab